Advanced search
Publication Cover
Journal of Inflammation Research Volume 14, 2021 - Issue
Submit an article Journal homepage
87
Views
9
CrossRef citations to date
0
Altmetric
Commentary

LRRK2-NFATc2 Pathway Associated with Neuroinflammation May Be a Potential Therapeutic Target for Parkinson’s Disease

Youcui Wang1 Institute of Brain Science and Disease, Qingdao University, Qingdao, People’s Republic of China;2 Shandong Provincial Key Laboratory of Pathogenesis and Prevention of Neurological Disorders, Qingdao University, Qingdao, People’s Republic of China;3 Shandong Provincial Collaborative Innovation Center for Neurodegenerative Disorders, Qingdao University, Qingdao, People’s Republic of ChinaView further author information
,
Xiaoqin Zhang1 Institute of Brain Science and Disease, Qingdao University, Qingdao, People’s Republic of China;2 Shandong Provincial Key Laboratory of Pathogenesis and Prevention of Neurological Disorders, Qingdao University, Qingdao, People’s Republic of China;3 Shandong Provincial Collaborative Innovation Center for Neurodegenerative Disorders, Qingdao University, Qingdao, People’s Republic of ChinaView further author information
,
Fenghua Chen1 Institute of Brain Science and Disease, Qingdao University, Qingdao, People’s Republic of China;2 Shandong Provincial Key Laboratory of Pathogenesis and Prevention of Neurological Disorders, Qingdao University, Qingdao, People’s Republic of China;3 Shandong Provincial Collaborative Innovation Center for Neurodegenerative Disorders, Qingdao University, Qingdao, People’s Republic of ChinaView further author information
,
Leilei Chen1 Institute of Brain Science and Disease, Qingdao University, Qingdao, People’s Republic of China;2 Shandong Provincial Key Laboratory of Pathogenesis and Prevention of Neurological Disorders, Qingdao University, Qingdao, People’s Republic of China;3 Shandong Provincial Collaborative Innovation Center for Neurodegenerative Disorders, Qingdao University, Qingdao, People’s Republic of ChinaView further author information
,
Jun Wang1 Institute of Brain Science and Disease, Qingdao University, Qingdao, People’s Republic of China;2 Shandong Provincial Key Laboratory of Pathogenesis and Prevention of Neurological Disorders, Qingdao University, Qingdao, People’s Republic of China;3 Shandong Provincial Collaborative Innovation Center for Neurodegenerative Disorders, Qingdao University, Qingdao, People’s Republic of ChinaView further author information
&
Junxia Xie1 Institute of Brain Science and Disease, Qingdao University, Qingdao, People’s Republic of China;2 Shandong Provincial Key Laboratory of Pathogenesis and Prevention of Neurological Disorders, Qingdao University, Qingdao, People’s Republic of China;3 Shandong Provincial Collaborative Innovation Center for Neurodegenerative Disorders, Qingdao University, Qingdao, People’s Republic of ChinaCorrespondence[email protected]
View further author information
Pages 2583-2586 | Published online: 16 Jun 2021

References

  • Gelders G, Baekelandt V, Van der Perren A. Linking neuroinflammation and neurodegeneration in Parkinson’s disease. J Immunol Res. 2018;2018:4784268. doi:10.1155/2018/4784268
  • Przedborski S. The two-century journey of Parkinson disease research. Nat Rev Neurosci. 2017;18(4):251–259. doi:10.1038/nrn.2017.25
  • Lee HJ, Bae EJ, Lee SJ. Extracellular α–synuclein – a novel and crucial factor in Lewy body diseases. Nat Rev Neurol. 2014;10:92–98. doi:10.1038/nrneurol.2013.275
  • Kim C, Ho DH, Suk JE, et al. Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat Commun. 2013;4:1562. doi:10.1038/ncomms2534
  • Kim C, Lee HJ, Masliah E, Lee SJ. Non-cell-autonomous neurotoxicity of α-synuclein through microglial toll-like receptor 2. Exp Neurobiol. 2016;25:113–119. doi:10.5607/en.2016.25.3.113
  • Dzamko N, Gysbers A, Perera G, et al. Toll-like receptor 2 is increased in neurons in Parkinson’s disease brain and may contribute to alpha-synuclein pathology. Acta Neuropathol. 2017;133(2):303–319. doi:10.1007/s00401-016-1648-8
  • Drouin-Ouellet J, St-Amour I, Saint-Pierre M, et al. Toll-like receptor expression in the blood and brain of patients and a mouse model of Parkinson’s disease. Int J Neuropsychopharmacol. 2014;18(6):18. doi:10.1093/ijnp/pyu103
  • Cookson MR. LRRK2 pathways leading to neurodegeneration. Curr Neurol Neurosci Rep. 2015;15(7):42. doi:10.1007/s11910-015-0564-y
  • Singleton AB, Gasser T. The discovery of LRRK2 mutations as a cause of Parkinson’s disease. Mov Disord. 2020;35:551–554. doi:10.1002/mds.27999
  • Li H, Su L-Y, Yang L, et al. A cynomolgus monkey with naturally occurring Parkinson’s disease. Nat Sci Rev. 2020.
  • Alessi DR, Sammler E. LRRK2 kinase in Parkinson’s disease. Science. 2018;360(6384):36–37. doi:10.1126/science.aar5683
  • Moehle MS, Webber PJ, Tse T, et al. LRRK2 inhibition attenuates microglial inflammatory responses. J Neurosci. 2012;32(5):1602–1611. doi:10.1523/JNEUROSCI.5601-11.2012
  • Russo I, Berti G, Plotegher N, et al. Leucine-rich repeat kinase 2 positively regulates inflammation and down-regulates NF-κB p50 signaling in cultured microglia cells. J Neuroinflammation. 2015;12(1):230. doi:10.1186/s12974-015-0449-7
  • Russo I, Bubacco L, Greggio E. LRRK2 and neuroinflammation: partners in crime in Parkinson’s disease? J Neuroinflammation. 2014;11(1):52. doi:10.1186/1742-2094-11-52
  • Kim C, Beilina A, Smith N, et al. LRRK2 mediates microglial neurotoxicity via NFATc2 in rodent models of synucleinopathies. Sci Transl Med. 2020;12:12. doi:10.1126/scitranslmed.aay0399
  • Dunne A, O’Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense. Sci STKE. 2003;2003(171):re3. doi:10.1126/stke.2003.171.re3
  • West AP, Koblansky AA, Ghosh S. Recognition and signaling by toll-like receptors. Annu Rev Cell Dev Biol. 2006;22(1):409–437. doi:10.1146/annurev.cellbio.21.122303.115827
  • Dzamko NL. LRRK2 and the immune system. Adv Neurobiol. 2017;14:123–143.
  • Dzamko N, Inesta-Vaquera F, Zhang J, et al. The IkappaB kinase family phosphorylates the Parkinson’s disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling. PLoS One. 2012;7(6):e39132. doi:10.1371/journal.pone.0039132
  • Fric J, Zelante T, Wong AY, Mertes A, Yu HB, Ricciardi-Castagnoli P. NFAT control of innate immunity. Blood. 2012;120:1380–1389. doi:10.1182/blood-2012-02-404475
  • Müller MR, Rao A. NFAT immunity and cancer: a transcription factor comes of age. Nat Rev Immunol. 2010;10:645–656. doi:10.1038/nri2818
  • Sompol P, Norris CM. Ca(2+), astrocyte activation and calcineurin/NFAT signaling in age-related neurodegenerative diseases. Front Aging Neurosci. 2018;10:199. doi:10.3389/fnagi.2018.00199
  • Manocha GD, Floden AM, Puig KL, Nagamoto-Combs K, Scherzer CR, Combs CK. Defining the contribution of neuroinflammation to Parkinson’s disease in humanized immune system mice. Mol Neurodegener. 2017;12(1):17. doi:10.1186/s13024-017-0158-z
  • Vasilopoulou F, Griñán-Ferré C, Rodríguez-Arévalo S, et al. I(2) imidazoline receptor modulation protects aged SAMP8 mice against cognitive decline by suppressing the calcineurin pathway. Geroscience. 2020. doi:10.1007/s11357-020-00281-2
  • Manocha GD, Ghatak A, Puig KL, Kraner SD, Norris CM, Combs CK. NFATc2 modulates microglial activation in the AβPP/PS1 mouse model of alzheimer’s disease. J Alzheimers Dis. 2017;58(3):775–787. doi:10.3233/JAD-151203

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.